Orlando Health, Inc.

Orlando, Florida 33806

5 studies enrolling now · 64 studies all time

What they study most

Acute Ischemic Stroke, Advanced Solid Tumors, Anaplastic Large-Cell Lymphoma, Atrial Fibrillation, Postoperative, Avascular Necrosis, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation, Biliary Tract Cancer, Blood Cancer, Breast Cancer, Breast Neoplasm Female, Breast Neoplasms

Studies at this site

• Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain After Gastric Bypass — Recruiting now
• BoxX-NoAF Clinical Trial — Recruiting now
• Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease — Recruiting now
• Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial — Recruiting now
• PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study — Recruiting now
• A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis — Running, not enrolling
• A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency — Completed
• Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis — Stopped early
• A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer. — Running, not enrolling
• A Multi-Centre Study in Patients Undergoing Total Hip Arthroplasty With the Smith+Nephew CATALYSTEM™ Primary Hip System — Running, not enrolling
• A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) — Completed
• Prospective Clinical Registry Evaluating Contemporary MANTA Outcomes — Completed
• Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening — Running, not enrolling
• Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] — Running, not enrolling
• A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations — Running, not enrolling
• Fluorescence Imaging of Carcinoma During Breast Conserving Surgery — Stopped early
• Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL) — Completed
• Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6 — Stopped early
• Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC) — Running, not enrolling
• Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC. — Stopped early
• A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease — Completed
• Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In — Completed
• A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma — Running, not enrolling
• Analysis of Both Sex and Device Specific Factors on Outcomes in Patients with Non-Ischemic Cardiomyopathy — Completed
• A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) — Completed
• Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer — Completed
• Clinical Investigation of the da Vinci Surgical System — Running, not enrolling
• Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers — Completed
• The TESLA Trial: Thrombectomy for Emergent Salvage of Large Anterior Circulation Ischemic Stroke — Completed
• A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant, — Stopped early
• A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132) — Completed
• Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer — Stopped early
• A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors — Completed
• An International Pulmonary Embolism Registry Using EKOS — Completed
• A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer — Completed
• Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy — Completed
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer) — Completed
• Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA) — Completed
• Open-Label Extension and Safety Study of Talazoparib — Completed
• Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL — Stopped early
• Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008 — Completed
• Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer — Completed
• EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) — Completed
• An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread — Completed
• A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma — Completed
• A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) — Completed
• Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma — Completed
• A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) — Completed
• ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas — Completed
• Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer — Completed